Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PTLA $29.32 4.0400 +15.98%
CERU $4.52 0.3000 +7.11%
PARD $0.16 0.0100 +6.67%
GLYC $7.40 0.4600 +6.63%
VICL $1.18 0.0600 +5.36%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $1.90 -0.2000 -9.52%
CBMG $19.11 -1.8800 -8.96%
CRIS $1.30 -0.1100 -7.80%
SNSS $6.62 -0.5200 -7.28%
ARWR $13.76 -1.0100 -6.84%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Making Cancerous Tumors Glow: Penn Researchers Use Infrared Imaging to Detect Lung Tumors

(Penn Medicine) Sept 24, 2014 - Penn Medicine researchers are now able to identify cancerous tumors of the lung using infrared imaging that makes hidden tumors glow during surgery.
read press release 



Less Costly to Screen For and Treat Early-Stage Lung Than to Treat Late-Stage Lung Cancer

(IASLC) Sept 24, 2014 - The average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography (LDCT) plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.
read press release 



Roche Says Avastin Prolongs Life in Breast Cancer Study

(Reuters) Sept 25, 2014 - Swiss drugmaker Roche said its cancer drug Avastin helped women with a common form of breast cancer live longer without their disease worsening, when used in combination with chemotherapy drug Xeloda.
read article 



Cancer Genome Sequencing Will Mean More Targeted Therapies

(Forbes) Sept 24, 2014 - As the cost of DNA sequencing plummets, the possibility of testing all cancer patients’ tumor genomes is becoming a reality.
read article 



Number Of Marketplace Insurers To Rise 25%: HHS

(WebMD News/Kaiser Health News) Sept 24, 2014 - The number of health insurance companies offering plans in the marketplaces this fall will increase by 25 percent, giving consumers more choices for coverage, Health and Human Services Secretary Sylvia Burwell announced Tuesday.
read article 



Penn’s Ezekiel Emanuel Wants to Die at 75

(Philadelphia Magazine) Sept 22, 2014 - And he’s making a lot of people angry because of it.
read article 



Celgene's Psoriasis Drug Gets Approval for New Indication

(Reuters) Sept 23, 2014 - Celgene Corp said the U.S. Food and Drugs Administration has approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.
read article 



Gilead's Latest HIV Pill Meets Study Goals

(Wall Street Journal) Sept 24, 2014 - Gilead Sciences Inc. said its new investigational combination pill for HIV met its primary study goals in two late-stage studies, boosting prospects that the biotech company will be able to contain anticipated generic competition to one of its biggest businesses.
read article (paid subscription required) 



NIH Exceptional Responders to Cancer Therapy Study Launched

(NIH) Sept 24, 2014 - The Exceptional Responders Initiative, a study to investigate the molecular factors of tumors associated with exceptional treatment responses of cancer patients to drug therapies, was launched today by the National Cancer Institute (NCI), part of the National Institutes of Health.
read press release 



Merrimack Does Well to License Marginal Cancer Drug to Baxter

(TheStreet) Sept 24, 2014 - Baxter has a hunger for cancer drugs with hair.
read article 



High Drug Co-pays Deny Needed Treatments

(San Francisco Chronicle) Sept 23, 2014 - Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of record profits, are aggressively attacking the cost of the innovative products developed by the biopharmaceutical industry.
read article (free registration required) 



IARC Calls on Countries with High Stomach Cancer Burden to Act to Prevent the Disease

(IARC) Sept 24, 2014 - A new report from the International Agency for Research on Cancer (IARC), the specialised cancer agency of the World Health Organization, urges health authorities of countries with high stomach cancer burden to include stomach cancer in their national cancer control programmes and allocate more resources to control the disease.
read press release 



AstraZeneca Launches New Website for People with Advanced Medullary Thyroid Cancer

(Yahoo! Finance) Sept 24, 2014 - Launched in conjunction with Thyroid Cancer Awareness Month, aMTCsupport.com offers resources and support for rare disease community.
read article 



Ohio State Opens First Fully Integrated Cancer Emergency Department

(OSUCCC - James) Sept 22, 2014 - For cancer patients with already compromised immune systems, what seems like a minor medical issue -- fever, dehydration, viral infection – can rapidly escalate into an emergency situation requiring care from a medical team familiar with managing the side effects of cancer treatment.
read press release 



From Distress Screening to Solutions: Patient-Centered Support

(ACCCBuzz) Sept 24, 2014 - The Edward and Marie Matthews Center for Cancer Care at the University Medical Center of Princeton at Plainsboro is a New Jersey cancer program with a tall vision to identify distress among their patients, no matter where they are within the organization, and refer them quickly to the help they need.
read article 



Four Researchers Awarded Grants to Investigate Effectiveness of Nintedanib* in Lung, Colorectal, and Gastrointestinal Cancers

(NCCN) Sept 24, 2014 - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib* (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.
read press release 



New Academic-Industry Partnership Creates Online Registry for Patients Tested for Inherited Cancer Risk

(MSKCC) Sept 23, 2014 - A newly formed consortium including experts from academic medical centers and commercial genetics laboratories across the country has established the Prospective Registry Of Multi-Plex Testing (PROMPT), an online registry for individuals and families who have undergone testing for inherited cancer-causing genetic mutations.
read press release 



ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

(Bayer HealthCare) Sept 24, 2014 - Positive results of the Phase III CONCUR trial of regorafenib in Asian patients with metastatic colorectal cancer to be presented in Proffered Paper Session; includes data from studies evaluating regorafenib, sorafenib and radium Ra 223 dichloride across six tumor types.
read corporate press release 



New Anticancer Peptide Vaccines and Inhibitors Developed by Ohio State Researchers

(OSUCCC - James) Sept 22, 2014 - Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort led by investigators at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
read press release 



Most Breast Cancer Patients Who Had Healthy Breast Removed at Peace with Decision

(Mayo Clinic) Sept 24, 2014 - More than 8 of 10 say they would make same choice again, Mayo Clinic study finds.
read press release 



Mass Spec: Coming to an OR Near You?

(MedPage Today) Sept 23, 2014 - Preliminary results in 14 patients show promise for mass spectrometry in breast cancer surgery.
read article (free registration required) 



Celgene's Revlimid Makes It Onto NHS for MDS

(PharmaTimes UK) Sept 24, 2014 - Certain patients with myelodysplastic syndromes have gained access to Celgene’s Revlimid (lenalidomide) after cost-regulators approved funding for its use on the National Health Service in England.
read article 



CEO to Step Down of Livestrong Group Founded by Cyclist Armstrong

(Reuters) Sept 23, 2014 - The CEO of the Livestrong cancer foundation started by disgraced cyclist Lance Armstrong announced his resignation on Tuesday after a tenure in which the organization went from a being global brand to losing millions after Armstrong's doping scandal.
read article 



Drug, Device CEOs Voice Concerns About O-Care Project

(The Hill) Sept 22, 2014 - Advocates for the drug, device and biotechnology industries are raising concerns about the implementation of a payments database required by ObamaCare.
read article 



Ebola Drug Trials to be Fast-tracked in West Africa

(Reuters) Sept 23, 2014 - Experimental Ebola drugs including compounds from Mapp Biopharmaceutical, Sarepta and Tekmira will be tested in affected West African states for the first time in a bid to fast-track trials, the Wellcome Trust said on Tuesday.
read article